JP2018502163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502163A5 JP2018502163A5 JP2017555860A JP2017555860A JP2018502163A5 JP 2018502163 A5 JP2018502163 A5 JP 2018502163A5 JP 2017555860 A JP2017555860 A JP 2017555860A JP 2017555860 A JP2017555860 A JP 2017555860A JP 2018502163 A5 JP2018502163 A5 JP 2018502163A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hepe
- disease
- composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 230000035558 fertility Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562104472P | 2015-01-16 | 2015-01-16 | |
| US62/104,472 | 2015-01-16 | ||
| PCT/IB2016/000202 WO2016113635A1 (en) | 2015-01-16 | 2016-01-15 | Compositions comprising 15-hepe and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017637A Division JP2020100627A (ja) | 2015-01-16 | 2020-02-05 | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502163A JP2018502163A (ja) | 2018-01-25 |
| JP2018502163A5 true JP2018502163A5 (cg-RX-API-DMAC7.html) | 2019-03-07 |
Family
ID=55697235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555860A Pending JP2018502163A (ja) | 2015-01-16 | 2016-01-15 | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
| JP2020017637A Pending JP2020100627A (ja) | 2015-01-16 | 2020-02-05 | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017637A Pending JP2020100627A (ja) | 2015-01-16 | 2020-02-05 | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20180008567A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3247348A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018502163A (cg-RX-API-DMAC7.html) |
| CN (2) | CN107405324A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1247136A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016113635A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018520197A (ja) * | 2015-07-21 | 2018-07-26 | アフィミューン リミテッド | 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物 |
| CN108697680A (zh) | 2015-12-18 | 2018-10-23 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
| JP2020145939A (ja) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | アレルギー性鼻炎抑制用組成物 |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| CN116098987A (zh) * | 2023-02-09 | 2023-05-12 | 华东医院 | 甘丙肽在制备治疗非酒精性脂肪性肝病药物中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
| CA2643972C (en) * | 2006-04-19 | 2012-01-03 | Peter Demin | Hepoxilin analog enantiomers |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| PL2858496T3 (pl) * | 2012-05-10 | 2023-09-11 | Solutex Na Llc | Oleje o działaniu przeciwzapalnym zawierające naturalne wyspecjalizowane mediatory prorozdzielcze i ich prekursory |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| RU2685706C2 (ru) * | 2014-01-10 | 2019-04-23 | Эфиммьюн Лимитед | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |
| JP6315536B2 (ja) * | 2014-01-29 | 2018-04-25 | 岩手県 | Ｐｐａｒ活性化剤 |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
-
2016
- 2016-01-15 JP JP2017555860A patent/JP2018502163A/ja active Pending
- 2016-01-15 HK HK18106960.3A patent/HK1247136A1/zh unknown
- 2016-01-15 WO PCT/IB2016/000202 patent/WO2016113635A1/en not_active Ceased
- 2016-01-15 CN CN201680013224.3A patent/CN107405324A/zh active Pending
- 2016-01-15 US US15/542,668 patent/US20180008567A1/en not_active Abandoned
- 2016-01-15 CN CN202111175690.0A patent/CN113893240A/zh active Pending
- 2016-01-15 EP EP16715081.2A patent/EP3247348A1/en not_active Withdrawn
-
2019
- 2019-01-11 US US16/245,878 patent/US20190216761A1/en not_active Abandoned
-
2020
- 2020-02-05 JP JP2020017637A patent/JP2020100627A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502163A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Neuroinflammation as a potential therapeutic target in Alzheimer’s disease | |
| JP2018537513A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| RU2018126361A (ru) | Композиции, содержащие 15-hepe, и способы их применения | |
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| JP2016535786A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524822A5 (cg-RX-API-DMAC7.html) | ||
| JP2020105186A5 (cg-RX-API-DMAC7.html) | ||
| Panza et al. | Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients? | |
| JP2016528301A5 (cg-RX-API-DMAC7.html) | ||
| JP2017515893A5 (cg-RX-API-DMAC7.html) | ||
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA45754A1 (fr) | Utilisation pharmaceutique d'une composition à base de pirfénidone à libération prolongée (pfd-lp) pour la réversion de la stéatose hépatique humaine (nafld/nash) | |
| JP2018507886A5 (cg-RX-API-DMAC7.html) | ||
| JP2019516739A5 (cg-RX-API-DMAC7.html) | ||
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| JP2016510340A5 (cg-RX-API-DMAC7.html) | ||
| JP2020100627A (ja) | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 | |
| JP2017505809A5 (cg-RX-API-DMAC7.html) | ||
| JP2015516988A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513650A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| JP2019507786A5 (cg-RX-API-DMAC7.html) |